Related Experiment Video
Updated: Aug 6, 2026
07:59
A High Throughput MHC II Binding Assay for Quantitative Analysis of Peptide Epitopes
Published on: March 25, 2014
An Immunoinformatic Approach for a Multi-Epitope Vaccine Against Toxoplasma gondii
Negar Asadi1, Leila Navapour2, Navid Mogharrab2
1Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
Parasite Immunology
|July 22, 2026
Summary
A novel multi-epitope vaccine candidate for Toxoplasma gondii (T. gondii) has been developed using key parasite epitopes. This potential vaccine shows promise for inducing immune responses, though further testing is needed.
Area of Science:
- Parasitology
- Vaccinology
- Immunoinformatics
Background:
- Toxoplasma gondii infection affects a third of the global population, causing severe outcomes, particularly in immunocompromised individuals, pregnant women, and infants.
- Currently, no effective human vaccine exists for T. gondii, highlighting a critical unmet medical need.
- The parasite's intracellular nature and apicomplexan classification present challenges for vaccine development.
Purpose of the Study:
- To design and computationally evaluate a novel multi-epitope vaccine candidate against Toxoplasma gondii.
- To incorporate B-cell, cytotoxic T-lymphocyte (CTL), and helper T-lymphocyte (HTL) epitopes from immunogenic T. gondii antigens.
- To assess the vaccine construct's immunogenicity, safety, stability, and potential interaction with immune receptors.
Main Methods:
- Identification of immunodominant epitopes from T. gondii SAG1, GRA6, and GRA7 proteins.
- Construction of a multi-epitope vaccine integrating B-cell, CTL, and HTL epitopes, with 50S ribosomal protein L7/L12 as an adjuvant.
- In silico analyses including molecular docking with TLR-4 and molecular dynamic simulations for stability and interaction assessment.
Main Results:
- The developed vaccine construct comprises antigenic, nonallergenic, nontoxic epitopes lacking human homologues.
- Computational studies indicated the vaccine's immunogenicity, non-allergenicity, and stability.
- Molecular docking revealed favorable interactions with the TLR-4 immune receptor, suggesting potential for initiating immune responses.
Conclusions:
- The in silico designed multi-epitope vaccine candidate shows significant potential for inducing primary immune responses against T. gondii.
- The construct's favorable predicted characteristics warrant further laboratory investigation for efficacy and safety validation.
- This approach offers a promising strategy for developing a much-needed vaccine against toxoplasmosis.
Related Concept Videos
00:42Cross-reactivity
Overview
01:28Toxoplasmosis
Toxoplasmosis, a zoonotic disease caused by the protozoan Toxoplasma gondii, poses significant public health challenges globally due to its high seroprevalence and varied clinical manifestations. As an obligate intracellular parasite, T. gondii can infect all warm-blooded vertebrates, but felids are its only definitive hosts, shedding unsporulated oocysts into the environment. Humans typically acquire the infection through ingestion of tissue cysts in undercooked meat or oocysts from...